Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

203.63 +4.04 (+2.02%)

Streaming Delayed Price Updated: 2:56 PM EDT, Jun 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

60 61 Next >

$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,800 Today ↗

October 03, 2023

Via Benzinga

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

September 29, 2023

From Biogen Inc.

Via GlobeNewswire

Is Biogen Stock a Buy Now? ↗

September 28, 2023

It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.

Via The Motley Fool

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Biogen Completes Acquisition of Reata Pharmaceuticals

September 26, 2023

From Biogen Inc.

Via GlobeNewswire

(BIIB) - Analyzing Biogen's Short Interest ↗

September 20, 2023

Via Benzinga

$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

September 15, 2023

Via Benzinga

Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗

September 25, 2023

Benzinga

Via Benzinga

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi ↗

September 25, 2023

Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

September 04, 2023

Via Benzinga

(BIIB) - Analyzing Biogen's Short Interest ↗

September 01, 2023

Via Benzinga

Analyst Ratings for Biogen ↗

August 29, 2023

Via Benzinga

Better Buy: Biogen vs. Eli Lilly ↗

August 29, 2023

This battle of biotech giants has a clear winner.

Via The Motley Fool

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

September 25, 2023

From Biogen Inc.

Via GlobeNewswire

California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims ↗

September 22, 2023

California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing...

Via Benzinga

Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy? ↗

September 09, 2023

Buying a biotech is a good move, but it might not be enough to entice investors.

Via The Motley Fool

7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth ↗

September 07, 2023

Finding the best pharma stocks to buy takes a little effort, but it will pay of with these seven long-term winners.

Via InvestorPlace

Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst ↗

September 06, 2023

B Riley Securities initiated coverage on Denali Therapeutics Inc (NASDAQ: DNLI) with a Buy rating and a

Via Benzinga

3 Healthcare Stocks to Sell in September Before They Crash & Burn ↗

September 06, 2023

The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023 ↗

September 06, 2023

Via Benzinga

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗

September 06, 2023

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...

Via Benzinga

Biogen Appoints Jane Grogan as Head of Research

September 06, 2023

From Biogen Inc.

Via GlobeNewswire

The 3 Best Biotech Stocks to Buy Now: September 2023 ↗

September 04, 2023

With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize.

Via InvestorPlace

Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment ↗

August 31, 2023

The company is now focusing on its launch in postpartum depression.

Via Investor's Business Daily

The 7 Most Promising Momentum Stocks to Own Now ↗

August 31, 2023

These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.

Via InvestorPlace

The 3 Most Promising Pharma Stocks to Own Now ↗

August 30, 2023

A pillar to economic growth in a defensive area, these promising pharma stocks are set to rise and give investors one bullish ride.

Via InvestorPlace

Wall Street Thinks This Tiny Biotech Company Could Soar Soon ↗

August 28, 2023

An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.

Via The Motley Fool

Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock ↗

August 24, 2023

Cassava had $168.4 million of cash at the end of June after losing $28.7 million during the second quarter of 2023. SAVA stock is up 5%

Via InvestorPlace

Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month? ↗

August 24, 2023

The pharmaceutical company's growth prospects have taken a big hit.

Via The Motley Fool

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.